Desidustat in the Treatment of Anemia in CKD
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 588 participants.
Also called NCT04012957
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 588 participants
- Sponsor
- Registry
-
NCT04012957
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- India
- Registry status
- Completed
Technical summary
Registry record NCT04012957. Randomized; no masking; primary purpose treatment. Start 2019-07-20 (actual); primary completion 2021-08-25 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Desidustat in the Treatment of Anemia in CKD
- Acronym
- DREAM-ND
- Condition
- Chronic Kidney Disease Stage 3
- Condition
- Anemia
- Condition
- Chronic Kidney Disease Stage 4
- Condition
- Chronic Kidney Disease Stage 5
- Intervention (Drug)
- Desidustat Oral Tablet
- Intervention (Drug)
- Darbepoetin Alfa
- Lead sponsor
- Zydus Lifesciences Limited
Record details
- Record id
cardio:ct-nct04012957- Content hash
81f9df36eff308a9dadf12e40963c6be0e8935f016231e4b8fec4efae027e0f0